OrsoBio Closes $67 Million Series B Financing to Advance Obesity Therapies
Slice of Healthcare Team
Sep 10, 2024
Key Highlights
- OrsoBio secures $67M Series B financing, led by Ascenta Capital and Woodline Partners.
- Proceeds will accelerate development of OrsoBio’s mitochondrial protonophore portfolio for obesity treatment.
- Dr. Evan Rachlin joins OrsoBio’s Board of Directors as part of the new investment.
Source: Business Wire
Notable Quotes
“ We believe that the future of obesity treatment will include GLP-1 RA-based combinations; this financing will enable us to build the scientific and clinical foundations to support our protonophores as components of these regimens. ”
Mani Subramanian, MD, PhD, CEO and Founder at OrsoBio
“ OrsoBio’s novel mechanisms hold promise to enhance weight loss, improve metabolic function, and preserve lean muscle mass. ”
Evan Rachlin, MD, Co-Founder and Managing Partner at Ascenta Capital
